Ladies and gentlemen, welcome to the HCA Third Quarter 2018 Earnings Conference Call. Today's call is being recorded. At this time, for opening remarks and introductions, I would like to turn the call over to Senior Vice President, Mr. Vic Campbell. Please go ahead, sir.
April, thank you very much and good morning everyone. Mark Kimbro, our Chief Investor Relations Officer and I would like to welcome all of you on today's call and also those of you listening to the webcast. With me here this morning are Chairman and CEO, Milton Johnson Sam Hazen, President and Chief Operating Officer and Bill Rutherford, CFO. Before I turn the call over to Milton, let me remind everyone that should today's call contain any forward looking statements, they are based on management's current expectations. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those that might be expressed today.
Many of these factors are listed in today's press release and in our various SEC filings. Several of the factors that will determine the company's future results are beyond the ability of the company to control or predict In light of the significant uncertainties inherent in any forward looking statements, you should not place undue reliance on these statements. The company undertakes no obligation to revise or update any forward looking statements whether as a result of new information or future results. On this morning's call, we may reference measures such as adjusted EBITDA and net income attributable to HCA Healthcare Inc. Excluding losses, gains on sales of facilities, losses on retirement of debt and legal claim costs, which are non GAAP financial measures.
A table providing supplemental information on adjusted EBITDA and reconciling to net income attributable to HCA Healthcare, Inc. To adjusted EBITDA is included in the company's 3rd quarter earnings release. As you heard, the call is being recorded and replay will be available later today. With that, let me turn the call over to Milton.
All right. Thank you, Vic, and good morning to everyone joining us on the call or the webcast. Before we go into details about the quarter, I'd like to take a few moments to talk about our response to Hurricanes Florence and Michael, which have recently affected our facilities and colleagues in the Southeast U. S. On September 14, Hurricane Florence made landfall in South Carolina.
And on October 10, Hurricane Michael made landfall in Panama City, Florida. Immediately before and after the storms, we evacuated several 100 patients to other facilities and without patient harm. Those storms had a devastating effect on communities we serve in Florida and the Carolinas and where our HCA colleagues live and work. Throughout these events, our colleagues in the affected areas and across the enterprise have supported our emergency operations efforts, our patients and each other. Our robust disaster preparedness plans give us confidence when facing weather disasters like this, but it's the teamwork and patient centered commitment of our HCA Healthcare colleagues that make those plans work so well.
I'm very proud of that teamwork and professionalism. Now, let me provide some comments on 3rd quarter results. Overall, we're very pleased with the 3rd quarter results. Consistent with recent results, we saw solid volume and rate growth, increased intensity of service and excellent expense management, which resulted in solid adjusted EBITDA growth for the quarter. This morning, we also favorably revised our earnings guidance ranges to reflect results for the 9 months ending September 30 and expectations for the remainder of the year.
More on this later in my comments. Revenues in the Q3 totaled $11,451,000,000 up 7.1% from the previous year's Q3. Net income attributable to HCA Healthcare Inc. Increased 78% to $759,000,000 or $2.15 per diluted share compared to $426,000,000 or $1.15 per diluted share in last year's Q3. Bill will provide more detail on these items in a moment.
Adjusted EBITDA in the 3rd quarter increased to 2,096,000,000 an 18% increase over the prior year, which included the negative impact from both hurricanes in the Q3 of last year and Texas Medicaid waiver payments. Additionally, our 3rd quarter adjusted EBITDA growth rate was unfavorably impacted by an estimated 3 10 basis points from the sale of Oklahoma University assets. Year to date through September, our adjusted EBITDA totaled $6,441,000,000 compared to $5,871,000,000 in the same period of 2017, an increase of 9.7%. Cash flows from operations were very strong, totaling $1,721,000,000 up from last year's 1 point $8,000,000,000 last year. We invested $846,000,000 in capital spending in our existing markets, repurchased $2,500,000 of our shares at a cost of $302,000,000 and also paid a dividend of 121,000,000 dollars during the Q3 of 2018.
This morning, we updated our guidance ranges for 2018. Revenues are now projected to range from $1,000,000,000 to $47,000,000,000 Adjusted EBITDA is estimated to range from $8,700,000,000 to $8,900,000,000 and diluted earnings per share is now estimated to range from $9.05 to $9.45 per diluted share. In September, we announced my retirement as CEO at year end and the appointment of Sam Hazen as CEO effective January 1, 2019. So today, after approximately 80 HCA quarterly earnings calls, this will be my last as an active participant. Since January 1, 2014, it's been my privilege to be the CEO of this great company.
I've had the distinct pleasure of getting to know many of you over my 36 years at HCA. This is a wonderful company with many talented people who are committed to delivery of high quality patient care and operational excellence. I am extremely proud of the many accomplishments we have achieved as a team, including advancing the company's clinical agenda, which focuses on delivery of high quality patient care and improving patient satisfaction. HCA is well positioned for the future under Sam's leadership and I remained excited about the company's future. Now, I'll turn the call over to Bill.
Thank you. Good morning, everyone. Bill, I should pause there just for a moment, recognize your leadership and the example you've set for all of us. So as Milt mentioned, we're pleased with our results as the company reported a solid Q3. On an as reported basis, our adjusted EBITDA was $2,096,000,000 or an 18% increase from our 1 point $776,000,000,000 reported in the Q3 of last year.
There are a few items I would like to discuss that impacted the year over year comparisons. First is the hurricane impact we experienced in the Q3 of 2017 where both Hurricane Harvey and Irma impacted our prior year results. You will recall we estimated the loss of revenues and additional expenses of approximately $140,000,000 or $0.24 per diluted share in last year's Q3. During the Q3 of this year, Hurricane Florence hit the Carolinas. Due to a mandatory evacuation order, we had to evacuate all of our patients from our Myrtle Beach Grand Strand Hospital.
We estimate we had an approximately $9,000,000 impact associated with Florence in this quarter. 2nd, the results for the Q3 2017 also included a negative impact to operating results related to the final settlement amounts for the program year ended September 30, 2017 for the Texas Medicaid waiver program of approximately $80,000,000 or $0.08 per diluted share. And third, as noted in our release this morning, based on the receipt of updated actuarial information, we recorded reduction to the company's reserves for professional liability risks of $70,000,000 or $0.15 per diluted share in this year's Q3. Finally, as we have noted in our previous quarters, based on this contribution last year, we estimate the sale of our Oklahoma facilities had a negative impact of approximately 3 10 basis points on the growth rate of adjusted EBITDA in the quarter. Our new facilities, which are primarily those facilities purchased in 2017 and the 1st 9 months of 2018, had a negative adjusted EBITDA of $27,000,000 in the Q3, which was consistent with the negative EBITDA in the Q3 of 2017.
So even when you adjust for these items, we are pleased with the performance and adjusted growth we experienced in the quarter. So now let me give you some more detail on the performance of some key operating metrics for the quarter as compared to the Q3 of 2017, starting with volume results by Para Class. Same facility Medicare admissions and equivalent admissions increased 2.9% and 3.5%, respectively. This includes both traditional and managed Medicare. Managed Medicare admissions increased 12.6% on a same facility basis and represented 37.6% of our total Medicare admissions.
Same facility Medicaid admissions increased 2.6%, while equivalent admissions increased 0.6%. Same facility self pay and charity admissions increased 8.8%. These also represented 8.8% of our total emissions compared to 8.3% in the prior year period. Texas and Florida still represent about 70% of our total uninsured admissions. Managed Care admissions increased 2.1% and equivalent admissions increased 4% on a same facility basis, a continuation of solid results.
Same facility emergency room visits declined 0.4%. Same facility self pay and charity ER visits represented 21% of our total ER visits compared to 20.2% in the prior year period. The decline in ER visits was primarily driven in our low acuity ER visits. Our level 1 through level 3 ER visits declined 3.8%, but our level 4 and 5 visits increased 1.8%. This is very similar to what we saw in the 2nd quarter as well.
Also, our same facility inpatient admissions through the ER increased approximately 3.3% in the quarter. Intensity of service or acuity increased with our same facility case mix increasing 3.8%. Same facility surgeries increased 3.2%. The same facility inpatient surgeries increased 1.6% and outpatient surgeries increased 4.2%. Same facility revenue per equivalent admission increased 3.9% in the quarter, primarily reflecting continued increase in the intensity of services during the quarter.
Our hospital only same facility managed care revenue per equivalent admission increased 4.8% in the quarter. Our same facility total uncompensated care, which includes implicit price concessions, charity care and uninsured discounts, totaled $6,342,000,000 in the quarter as compared to $6,616,000,000 reported in the prior year. This growth was in line with our volume and pricing results. Now turning to expenses and operating margin. Our as reported adjusted EBITDA increased 170 basis points from 16.6 percent in the Q3 last year to 18.3% on an as reported basis.
Some of the improvement in margin can be attributed to loss of revenue and increased costs in the prior year's Q3 due to hurricanes. The sale of our Oklahoma facilities and our new facilities had an estimated 110 basis points unfavorable impact on our adjusted EBITDA margin for the Q3 of 2018. Same facility operating expense per equivalent emission increased 1.8% compared to last year's Q3. This metric benefited from the impact of the prior year hurricanes. Adjusted for this, the current year increase is in line with recent trends.
On a consolidated basis, salaries and benefits as a percent of revenues were 46.9% compared to 47.5% in last year's Q3. On a same facility basis, salaries and benefits as a percent of revenue were 43.7% versus 44.8% last year. And same facility salaries per equivalent admission increased 1.4 percent in the quarter. Overall, our labor costs remained relatively stable. Supply expense as a percent of revenue was 16.5% this quarter as compared to 16.6% in last year's Q3.
On a consolidated basis, supplies as a percent of revenue declined 10 basis points and same facility supply expense per equivalent emission increased 3 percent for the Q3 compared to the prior year period. Other operating expenses declined 100 basis points from last year's Q3 to 18.4 percent of revenues. $70,000,000 reduction in our provision for professional liability risk recorded in the 3rd quarter. Let me touch briefly on cash flow. Cash flow from operations totaled $1,721,000,000 for the Q3 of 2018 compared to $1,008,000,000 in last year's Q3, which is an increase of almost 71%.
Free cash flow, which is cash flow from operations of $1,721,000,000 less capital expenditures of $846,000,000 distributions to non controlling interests of $130,000,000 and dividends paid to shareholders of $121,000,000 was $624,000,000 in the quarter compared to $164,000,000 in Q3 of 2017. At the end of the quarter, we had $2,382,000,000 available under our revolving credit facilities and debt to adjusted EBITDA was 3.76 times at September 30, 2018 compared to 4.02 times at the end of 2017. Now moving to earnings per share. Our diluted earnings per share in the quarter totaled $2.15 up from $1.15 in the Q3 of last year. Our EPS was impacted by the items I previously discussed as well as a 0.37 dollars per diluted share tax benefit related to the impact of the Tax Cuts and Jobs Act.
Also, we estimate our divestiture of OU operations coupled with the impact of our new facilities had approximately $0.10 negative impact on EPS in the quarter as compared to the prior year. So that concludes my remarks and I'll turn the call over to Sam for some additional comments. All right. Good morning, everyone. I'm going to
provide more detail on our volume performance for the quarter as compared to the Q3 of last year. In general, our volume growth in the quarter was consistent with the prior 2 quarters' growth. Additionally, we continue to demonstrate broad based growth across the company's divisions and across our various service lines. My comments will focus on our same facilities' domestic operations. 12 of 14 divisions had growth in both admissions and adjusted admissions.
5 of 14 divisions had growth in emergency room visits. Freestanding emergency room visits grew 11%, while hospital based emergency room visits declined 1.8%. Once again, higher acuity visits grew, while lower acuity visits declined. Admissions through the emergency room, as Bill indicated, grew by 3 point 3%. Trauma and EMS volumes grew by 4.9% and 1.5%, respectively, reflecting the higher acuity visits we are seeing in our emergency rooms.
Inpatient surgeries were up 1.8%. Surgical admissions were 27.3 percent of total admissions in the quarter, generally consistent with the prior year. Surgical volumes continued to be strong in cardiovascular, vascular and orthopedic service lines. 11 of 14 divisions had growth in inpatient surgeries. Outpatient surgeries showed strong growth, hospital based surgeries were up 5% and our freestanding ambulatory surgery centers were up 3.8%.
13 of 14 divisions had growth in outpatient surgeries. Behavioral health admissions grew 2.4%, rehab admissions grew 8.3%, cardiology procedure volumes, both inpatient and outpatient combined, were up 2.3%, driven mostly by growth in electrophysiology services. Births were down 1.2% and neonatal admissions were down 1.6%. Urgent care visits for the company were down 2.8% on a same facilities basis. They were up however 12% on a consolidated basis, reflecting the growth in the number of overall centers.
HCA has now grown same facility admissions in 18 consecutive quarters. Before I finish my comments, I want to take this time to acknowledge Milton and thank him for his outstanding leadership and for being a great colleague. With almost 37 years of service with the company, Milton has had a tremendous career. On behalf of the senior team and the Board of Directors, we wish him the best upon his retirement at the end of the year. Also, I want to share a few thoughts I shared with our Board about the company's current state and my view on the company's near term future.
I believe this consistent pattern of growth that HCA demonstrates is a result of multiple factors. First, macro trends in our markets are mostly positive. Demand growth is solid and trending favorably. Pricing trends remain stable and we believe we have good visibility into them over the next few years and the competitive environment remains fragmented, which creates an advantage for us given our scale and diversification. 2nd, the company's growth agenda underneath these macro trends is once again yielding solid market share gains.
Our overall competitive position in our diversified portfolio of markets is strong as a result of improvements in quality outcomes, improvements in nursing performance and strategic capital spending, which is adding appropriate inpatient and surgical capacity along with more outpatient facilities to serve our patients conveniently. And 3rd, HCA is fortunate to have a deep and experienced management team that is fully engaged and relentlessly focused on execution and delivering results that create value for our patients, our employees, our physicians and our shareholders. I believe these three factors will continue to support our business in 2019. Typically, we do not provide any indication into the upcoming year at this point. But with the transition and leadership, I felt it important to give a glimpse into the upcoming year.
While we can never predict with certainty how our business will perform, the environment in 2019 appears positive in general across our markets and specifically with respect Our planning process for 2019 is not finished. As usual, we will provide you with more details in January when we formally issue guidance for the year. An early look, however, at 2019 indicates that we expect solid volume growth again and an adjusted EBITDA growth rate somewhere within a reasonable range of this year's currently expected full year growth rate. As we always do at HCA, we will challenge ourselves to find opportunities to enhance performance. I've been with HCA for 36 years and it is truly an honor to be the next CEO.
HCA is a great company and I look forward to working with our employees and physicians as we strive to achieve our mission, which is fundamentally to give our patients the care they deserve. With that, let me turn the call over to Vic for questions.
All right. Thank you, Sam and everyone. With that, April, if you'll open the queue for questions. And I do encourage each of you to limit your questions to 1 because I think we have several in the queue.
Thank We'll take our first question from Justin Lake from Wolfe Research. Please go ahead.
Thanks. Good morning. First, let me just first say goodbye to Milton. It's been a good run. And Sam, congratulations on new role, well deserved.
And thank you very much for providing that 2019 viewpoint. I know everyone appreciates it. It. So my question is going to be around that. Specifically, Sam, you said growth for 2019 should be in the range of 2018.
2018 obviously had a lot of moving parts in terms of good guys and bad guys. But the reported number looks like about 7%. So I just want to confirm that that's what your that's the number we should kind of focus on there for expected growth year over year in EBITDA?
Yes, Justin, this is Bill. Our midpoint of our guidance, you're right, would suggest just under a 7 percent as reported year over year growth.
Okay. And that's there's no other moving parts. We should expect a range, midpoint of a range for next year to be about that 7%?
Well, I don't
want to give percentage. We obviously yes, I don't want to give specific percentages on there. As we look at the factors, we look at the trends around the core growth, we look at capital continue to come online, we look at the turn of the trend on acquisitions and all those together believe that we should be within a reasonable range of this year's growth rate.
Okay. And if I could just follow-up with the for Q4, your implied guidance seems to have a core growth rate in the 3.5% range. So I'm curious if there are any moving parts I should be thinking about there as maybe there's hurricane weakness in that Q4 given the hurricanes down south or any other kind of moving parts. And obviously it seems like there's a little bit of a difference between 3.5 percent and 7 percent for next year.
Yes. So let me call out a couple of points when you're looking at our guidance and then what the expected range of growth for this year's Q4 is. First, just to remind everybody, the Q4 of 'seventeen was an extremely strong quarter for us. We posted a little north of 7% growth over the prior year in that quarter. 2nd, when we look at the sequential Q3 to Q4 growth, our estimate would be similar to somewhat exceed what we typically see.
We've studied the seasonality and we factored that into our guidance. 3rd, as you mentioned, we do have some uncertainty regarding the Q4 impact of Hurricane Michael on our Florida Panhandle operations. We tried to factor a reasonable estimate into that or the quarter into our guidance. And finally, when I really look at our updated guidance, as you see at the midpoint, we've increased approximately $50,000,000 at the midpoint. It's basically accounting for the professional liability pickup we had this quarter, offset by some impact of Michael in the quarter as well.
So that's really the factors that went into our overall guidance for the balance of the year. Okay.
Thank you, Justin.
Yes.
And Milton is really not going away.
I was going to
say one thing
on the 2019 guidance just to be clarified too. It does not include acquisitions such as Mission. That is not included in the range that Sam stated, just to make that clear as well.
Thanks again.
And we'll take our next question from Frank Morgan with RBC Capital Markets. Please go ahead.
Good morning and congratulations Milton and best wishes. I guess to follow-up on that capital deployment and acquisition question. I'm just curious is there anything that we should expect to be different with regard to just the cadence of capital deployment that might affect sort of how your volume growth plays out over the next year? And then on that topic of Mission Health, any thoughts around how you specifically would fund that transaction? Thanks.
Yes. Frank, I'll start with the latter. We're still in the process of the Mission Health acquisition. Likely that would be a public market event, but we'll evaluate that just as we get closer and have visibility of a close date. Regarding capital next year and impact, obviously, we'll talk about that further when we give when we complete our planning process and give full year 2019 guidance with specifics.
The capital will be a factor that will help contribute the growth trajectory of the company.
Yes. This is Sam, Frank. I mean, we have about 4 $1,000,000,000 to $5,000,000,000 of capital in our pipeline. We will have a little bit more come online in 2019 than we had in 2018. It comes online at different points in the year.
So it will have different impacts, if you will, on our volume. But I don't think it's going to materially change our volume trends or expectations as we finish up this year and go into next year. We are seeing improving demand in our markets, as I mentioned in our call, I mean in my comments rather. And we've seen that now for roughly 3 or 4 straight quarters. So we're encouraged by that.
And then as I mentioned, we are starting to see market share gains again, which is encouraging with what we're doing in the marketplaces around our growth agenda.
All right. Thank you, Frank.
And we'll take our next question from Peter Costa with Wells Fargo Securities. Please go ahead.
Thanks guys and congratulations to both on the transition and management. My question is regarding the is HCA entering into a new phase of your growth? You've talked about I know you talked about the 7 percent -ish growth in EBITDA for next year as being next year. But your long term guidance of 4% to 6%, that's above that. And then we start looking at acquisitions and you're starting to do some acquisitions outside your markets of significant hospital systems, whether it be Savannah or Asheville.
So are we approaching a new phase of growth for you guys in terms of new markets?
Well, this is Sam. I think Asheville and Savannah uniquely offered up opportunities for the company that met our criteria. Both of those systems are fundamentally market makers in the sense that they can execute on their own what we believe to be the right provider system strategy. For I would hope that we would see continued opportunities for new markets. Obviously, our interest is primarily inside of our existing portfolio.
But to the extent we see a new market that presents a system that has the wherewithal to go the distance, if you will, we would be very interested in that. Now obviously, those systems come up when they come up. We can't really forecast that, but we will continue to be opportunistic around those situations when they present themselves.
Thank you. Is there
some change that's causing them to show up now as opposed to over the last decade?
Well, the story around Savanna and Mission are totally different. Savanna was in a desperate situation, needed more capital, needed professional management and so forth. Mission conversely is a very successful system, well managed, great physicians, great financial results and so forth. They just viewed the need for scale as being very significant at least in their thinking and their Board made a decision to go down that path with us. So it just depends on the circumstances.
Obviously, we believe Savanna has incredible long term potential. And the size of that healthcare market is about 1,000,000 people when you consider the rural market, which is very similar to the Asheville market and the Western North Carolina rural markets combined. So those kind of situations are really dependent upon the individual circumstances and the strategic analysis that each of the boards take. So I don't know if there's anything today that's materially different that would suggest there's going to be more, but just have to wait and see how that goes. I think the company is poised to take on more, both from a balance sheet standpoint as well as an organizational capacity standpoint.
We think over time, these are going to be very productive healthcare systems for the company.
Thank you. Thank you, Pete.
We'll take our next question from Brian Tanquilut from Jefferies. Please go ahead.
Hi, good morning and congrats to both of you guys. Bill, just a couple of quick questions for you. As I think about the D and A accrual for the quarter, it ticked up year over year and sequentially. Anything to call out there? And then just back to the question on funding for Mission, are you thinking of using unsecured notes in that one?
And also what are your thoughts on investment grade? Thanks.
Yes, thanks. On the depreciation, that growth is really just factor of our same store as well as new acquisitions that are fueling that and pretty much in line with what we anticipated on there. Relative to Mission Financing and the specific metrics, too early to call. We'll evaluate that at the time what the market conditions are and we'll look at. In terms of our pursuit of investment grade, we haven't stated that as a specific financial goal, but I think as we continue to demonstrate consistent performance, strong balance sheet, great cash flow that hopefully over time will be recognized for those trends.
All right. All right. Thank you. Thanks, Brian. Yes.
And we'll take our next question from Michael Mushel from Evercore ISI. Please go ahead.
Thanks. Well, since the last call, the Medicare IPPS rule is finalized for fiscal 2019. So could you just quantify how much better you think that will be for you than the recent trend and whether it was an incremental Medicare reimbursement factored into the guidance for this calendar year for Q4?
Yes. You got to take that? Yes.
I'll cover that. Thanks for the question. So we are getting a favorable update. As we assess it now, our update will range between 2.5% to 2.8% growth in our Medicare update. That is compared to approximately 1% we received in recent past.
So that's an incremental 1.5% to 1.8% on the Medicare update. We believe we have accommodated for this within the context of our overall guidance range and perhaps will be a factor for us as we look towards 2019 as well.
Great. Thank you. Thank you. Thanks, Michael.
We'll take our next question from A. J. Rice from Credit Suisse. Please go ahead.
Thanks. Hi, everybody. Congratulations to Sam and Milt, we wish you the best. I was looking back at the envelope. It looks like the stock is up almost 3 times since you were named Chairman.
So that's quite a run-in 5 years. Congratulations on that. Just I guess my question would be, a lot of improvement in margin this quarter and the last few quarters has been driven by the top line performance, strong volumes, strong pricing. I wonder if you guys could spend a minute just talking about what's happening on the individual expense lines. I know there's a little of that in the prepared remarks, but is there any area where you're seeing the expenses whether it's labor, supplies, other in and of themselves opportunities for improvement or any place where you're facing a headwind on the cost side?
A. J, this is Sam. We are very pleased with the performance of the company operationally over the past year or so. Our teams have stepped up, especially on the human resources side of the equation and had a dramatic impact on our nursing performance. Our nursing contract labor on a year over year basis is down significantly.
We've been able to increase our hiring as a result of our nursing agenda and human resources agenda. So at this particular point in time on the labor front, we're not anticipating any unusual headwinds as we turn the calendar into 2019. We will continue to execute on the core elements of what we're trying to get done with being a very productive employer and at the same time a great employer for our employees and we think that's going to yield some dividends as we move forward. Obviously, it's important that we grow our volume simply because we get the operating leverage from that growth given the fixed cost structure of the company. On the other two categories, I would say that the trends are generally consistent.
We're not seeing anything unusual at this particular point in time on either the supply line item or the other operating expenses. We have been able to manage our physician costs effectively. In this particular quarter, I think our physician costs as a percent of revenue were consistent with the previous years. So we haven't seen any dramatic shift there as well. So as we turn into 2019, again, we'll have to get through all the details of our planning over the next 60 days or so, but we're not anticipating any material swing in any of the cost trends.
All right. Okay. Thanks, Jay. Thank you very much.
And we'll move on to our next question from Ralph Giacobbe from Citi. Please go ahead.
Thanks. Good morning. Just quickly want to go back. Mission, are you willing to give us an EBITDA run rate? I think we had thought about sort of $130,000,000 to $140,000,000 I don't know if you want to sort of comment on sort of the baseline there.
And then my question was really on you called out hospital only same facility revenue per adjusted admission of the 4.8% within managed care. One is there a reason you make the distinction of hospital only? And then if I take that percentage and the adjusted admission number that you provided the 4% it would suggest managed care revenue up close to 9%, seems like a pretty hefty number. Maybe just some commentary on kind of factors driving that aside from just the easier comp? Thanks.
All right.
Yes. Let me start with that. We give the hospital only managed care just as you look at the consolidated number gets affected by physician practice, urgent care and others. So we're just trying to provide some clarity on there. We remain pleased with managed care number.
There clearly an intensity driver of that as well as pricing factor of that. We're pleased with our contracting efforts. We've got good visibility into 2019 and 2020 as well pretty consistent terms and condition that we've experienced. There are potentially when you look at the quarter over quarter results, some hurricane impact as a result as you had recovery of some hospital based outpatient surgeries this year as well. So again, overall, please that 4.8% is pretty consistent on that stat with what we've seen year to date running about the same number.
So it's been pretty stable trends for us on that Managed Care book.
And did you want to comment on the mission run rate or at this point in time?
Yes. I think honestly it's too early for us to give some commentary on that. As we get into our 2019 guidance and we get closer visibility into that transaction, we'll give you guidance on what we expect the contribution of Mission will be.
Good. Okay.
Thank you, Ralph.
We'll move on to our next question from Steven Valiquette from Barclays. Please go ahead.
Thanks. Good morning, everyone. Thanks for taking the question. My question, I guess, is somewhat similar to the one that was just asked, but just to kind of stick with that topic a little bit. I mean, the strength in same store revenue per admission, it definitely seems to be a common theme really within the overall hospital industry this quarter.
You had some nice reacceleration as well. But just curious if you can remind us again how much that's driven by raw pricing benefits or perhaps some acceleration of the mix shift to greater acuity in the inpatient setting, which has been really talked about a lot this year. Just want to get more color on that last one in particular. Thanks.
Bill, you want that one?
Well, there's clearly an intensity driver of that as we continue to focus our strategic efforts of growing our high intensity business. That's driving that statistic as well. So I would give you our case mix number. We've seen that grow pretty consistent in the 3% to 4%, sometimes north of that over the past several quarters. And that's really just a function, I think, of our strategies and new capital and focus on program development is the main driver of that.
And as we've seen continued growing demand in the market too, all of those are driving higher inpatient growth that's fueling that revenue per adjusted admission number as well.
I mean just to give you some color, this is Sam again. I mentioned in my prepared comments that our TAMA volumes were up 4 percent plus. Just to give you another example, our bone marrow transplants inside of HCA in the quarter were up 16%. Our orthopedicsurgical volumes, which carry a higher revenue per case than average, were up significantly. Cardiovascular services also carrying a higher revenue per case.
Those are contributing factors to this. I think when you look fundamentally at the pricing component of our business, we're achieving what we thought we would both on the commercial side as well as the governmental side. And then as you look at the strategic agenda of the company, which is to create more clinical capabilities, those additional clinical capabilities allow us to take care of more acute patients, provide more complex procedures and that drives our revenue up. Again, that's a very powerful model for us because it's on the same platform of fixed costs. And if we can increase the acuity in our facilities, deliver the higher revenue per patient, put that on top of the same fixed costs, it produces a decent margin lift for the company.
So that's been our strategy. We continue to execute on it. We think we have headroom in it. As we build out our outpatient facilities in each of our markets, we think that opens up the gateway, if you will, to an HCA provider system. And then when our patients need more complex care, we can provide it to them somewhere else in the system.
That's fundamentally what we've been about for the past 5 or 6 years, and we continue to believe that's adding value to the company.
Okay. That's helpful color. Thanks.
We'll take our next question from Josh Raskin from Nephron Research. Please go ahead. Josh, please go ahead. Josh, are
you there?
All right. Let's move on.
We'll move on to our next question from Ana Gupte from Leerink Partners. Please go ahead.
Hey, thanks. Good morning. Hey, congrats, Milt. Congrats, Sam. Look, the question was about the managed care payer mix, which continues as you say to show improvement.
And last time, I think you talked a little bit about the labor market data by your various markets. Can you give us any market specific color on what's going on? Your surgical volumes are really strong for a generally seasonally weak quarter. And then on the ED side, at what point do you think this might turn potentially even inflect into positive? At what point does even the Level 3 admission Level 3 ED visits stop kind of mix shifting to urgent care or freestanding?
That was pretty good. You just snuck 3 questions. We'll give you a break.
Again, we had broad based performance across a lot of our markets in the quarter. And I think that's a continuation of what we've seen in the first half of the year. But in particular, we had strong performance in our DFW market. We had strong performance in our Austin, Texas market. Our North Florida markets were very strong in the quarter.
So very powerful results across this wonderful portfolio that we have of markets. And it's broad based, it's not just in admission activities, it's in other categories of our business, which is encouraging and again reflects the strength of HCA's portfolio, not only from a market standpoint, but from a service line standpoint, given that we provide so many different services. As it relates to the emergency room, we have seen growth for the year. It's modest. I mean, we're up about 1% for the year.
Clearly, we benefited earlier in the year from flu activity. We have seen somewhat of a slowdown in supply in our markets with respect to freestanding emergency rooms and certain urgent care center development. So maybe over the long term, we could possibly start to see some rebound in the emergency room volume. Again, what we are soft in are the lower revenue elements of our emergency room business. Our higher levels of acuity are producing much more revenue per visit than do the lower levels obviously, in how we price.
And so the profitability impact of it is not as material as one would think. Nonetheless, we have seen some softness. Some of that could possibly be cannibalized by our own urgent care center development, which we think is a very strategic element of what we're trying to do in being comprehensive in the offerings of provider system capability and convenience for our patients, as well as having different price points, if you will, for our payer partners. And so from that standpoint, we may be cannibalizing a little bit of our own business. But long term, we think it's strategic to building out the provider capabilities that we think are necessary for us to be responsive to the marketplace.
Super helpful. Thank you.
All right. Thank you, Adam.
We'll move to our next question from Josh from Nephron Research. Please go ahead.
I think he must
have gotten cut off because Josh is more verbal than this.
All right.
Anyone else in there?
Go to the next. All right. Next question.
We'll move on to Kevin Fishbank from Bank of America. Please go ahead.
Great, thanks. Just wanted to go back to the Q4 guidance commentary because it's still trying to square that one out. I guess the last quarter, I think you said that the guidance did not include DISH, which we were estimating was going to be like a $50,000,000 or $60,000,000 boost. So I would have thought that the guidance would have raised by at least that much. But then to your point about the liability adjustment minus the hurricane, so why isn't the guidance raised more like $100,000,000 than the $50,000,000 number?
Yes, Kevin. This is Bill. I think your number is a little higher when we equate it to the percentage growth. Then I don't think we're seeing that 50% to 60%. It's probably more in the 35% to 40% level for us.
And I do think that as you look at our range of guidance that it could potentially put us on the higher to the midpoint. So I think the range is wide enough to accommodate for that Medicare update.
Okay. So you kind of feel like that could get you to the higher end of the range?
Potentially. And there's obviously a lot we got a lot of revenue. There's a lot of pluses and minuses that flow through in any given time. But again, I think we feel comfortable with where our guidance is today given all the factors that we're looking at? I think the business dynamics, we're not anticipating any dynamic change as we go from the Q3 to the Q4.
I mean, some of this is we think encouraging with respect to how our volumes have sustained themselves over the years. So we're optimistic that the trends of the company will continue on into the Q4 and into 2019 like we mentioned. So there's a lot of moving parts in our business, but nonetheless, the key elements are pretty consistent with how we've been operating.
Okay. So basically this is
an in line quarter for you guys and in line guidance. The only changes are just going to be outside of the core performance metrics.
I think that's right, Kevin. Yes.
I think that's fair. All right. All right. Any other questions remain? All right.
April, I think we're good. And I thank everyone for dialing in and look forward to talking to you in the menu. Thank you very much. Thanks, April.
This concludes today's presentation. We thank you for your participation. You may now disconnect.